Report date: Apr 16, 2024
Conflict count: 351559
Publisher: Case Journals
Title count: 1
Conflict count: 184


==========================================================

Created: 2019-04-09 20:34:25.0
ConfID: 5458597
CauseID: 1442812580
OtherID: 1441051145, 1441906906, 1442812580
JT: Case Medical Research
MD: Case,null,null,null,2019,Rheumatology I: Rheumatoid Arthritis
DOI: 10.31525/cmr-d62285(Journal) (5458597-N )
DOI: 10.31525/cmr-fbd68c(Journal)
==========================================================

Created: 2019-05-03 21:32:14.0
ConfID: 5466662
CauseID: 1444541238
OtherID: 1444541238
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Lynparza,olaparib
DOI: 10.31525/cmr-c84f02(Journal) (5466662-N )
DOI: 10.31525/cmr-112db43(Journal)
==========================================================

Created: 2019-05-03 21:35:59.0
ConfID: 5466936
CauseID: 1444542038
OtherID: 1444542038
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Eflornithine, Treatment of familial adenomatous polyposis
DOI: 10.31525/cmr-116dee0(Journal) (5466936-N )
DOI: 10.31525/cmr-116def0(Journal)
==========================================================

Created: 2019-05-03 18:06:59.0
ConfID: 5468226
CauseID: 1444527727
OtherID: 1442079816
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Diabetes Mellitus, Type 2, Date of authorisation: 22/12/2011, Revision: 5, Status: Authorised
DOI: 10.31525/cmr-ebb00c(Journal) (5468226-N )
DOI: 10.31525/cmr-3996c9(Journal)
==========================================================

Created: 2019-09-21 05:52:28.0
ConfID: 5468612
CauseID: 1454618187
OtherID: 1454618187
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Dupixent,dupilumab
DOI: 10.31525/cmr-c84efd(Journal) (5468612-N )
DOI: 10.31525/cmr-1d3ecb5(Journal)
==========================================================

Created: 2019-05-03 18:27:29.0
ConfID: 5468738
CauseID: 1444529257
OtherID: 1442079816
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Methylthioninium, treatment of frontotemporal dementia with parkinsonism-17
DOI: 10.31525/cmr-ebb010(Journal) (5468738-N )
DOI: 10.31525/cmr-eb27fd(Journal)
==========================================================

Created: 2019-05-03 18:27:44.0
ConfID: 5468740
CauseID: 1444529267
OtherID: 1442079816
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Methylthioninium, treatment of progressive non-fluent aphasia
DOI: 10.31525/cmr-ebb00a(Journal) (5468740-N )
DOI: 10.31525/cmr-eb27ff(Journal)
==========================================================

Created: 2019-05-03 18:27:44.0
ConfID: 5468741
CauseID: 1444529267
OtherID: 1442079816
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Methylthioninium, Treatment of progressive supranuclear palsy
DOI: 10.31525/cmr-ebb014(Journal) (5468741-N )
DOI: 10.31525/cmr-eb2801(Journal)
==========================================================

Created: 2019-05-03 18:27:44.0
ConfID: 5468742
CauseID: 1444529267
OtherID: 1442135350
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Mozobil,plerixafor
DOI: 10.31525/cmr-ed3b4e(Journal) (5468742-N )
DOI: 10.31525/cmr-eceeab(Journal)
==========================================================

Created: 2019-05-03 18:27:44.0
ConfID: 5468743
CauseID: 1444529267
OtherID: 1442135350
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Imnovid (previously Pomalidomide Celgene),pomalidomide
DOI: 10.31525/cmr-ed3b4b(Journal) (5468743-N )
DOI: 10.31525/cmr-eceeac(Journal)
==========================================================

Created: 2019-05-03 20:23:14.0
ConfID: 5468753
CauseID: 1444536342
OtherID: 1444529419, 1444529465, 1444529486, 1444529502, 1444529732, 1444530915, 1444531559, 1444532554, 1444532577, 1444532687, 1444532998, 1444533000, 1444533135, 1444534681, 1444535021, 1444535087, 1444536342
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2000,[Trial of device that is not approved or cleared by the U.S. FDA]
DOI: 10.31525/ct1-nct03897751(Journal) (5468753-N )
DOI: 10.31525/ct1-nct03839199(Journal)
==========================================================

Created: 2019-05-09 09:01:47.0
ConfID: 5477217
CauseID: 1445305826
OtherID: 1444529267
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised
DOI: 10.31525/cmr-ed3b4f(Journal) (5477217-N )
DOI: 10.31525/cmr-eceead(Journal)
==========================================================

Created: 2019-10-13 15:08:06.0
ConfID: 5536998
CauseID: 1456117660
OtherID: 1456117620
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,The Impact of Electroacupuncture on Clinical Effect,Brain Structural and Functional Changes on Spinal Cord Injury
DOI: 10.31525/ct1-nct03909958(Journal) (5536998-N )
DOI: 10.31525/ct1-nct03909087(Journal)
==========================================================

Created: 2019-10-13 15:39:21.0
ConfID: 5537491
CauseID: 1456118748
OtherID: 1456118508
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Gut Microbiota Pilot Study
DOI: 10.31525/ct1-nct03897023(Journal) (5537491-N )
DOI: 10.31525/ct1-nct03892590(Journal)
==========================================================

Created: 2019-10-13 16:55:51.0
ConfID: 5537888
CauseID: 1456121067
OtherID: 1456119438, 1456119562, 1456121067
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,PoNS Clinical Experience Program (TBI)
DOI: 10.31525/ct1-nct03882554(Journal) (5537888-N )
DOI: 10.31525/ct1-nct03852732(Journal)
==========================================================

Created: 2019-10-13 17:19:21.0
ConfID: 5538684
CauseID: 1456121761
OtherID: 1456117588
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Wrist Worn Blood Pressure Measurement
DOI: 10.31525/ct1-nct03911349(Journal) (5538684-N )
DOI: 10.31525/ct1-nct03919136(Journal)
==========================================================

Created: 2019-10-13 17:31:51.0
ConfID: 5538756
CauseID: 1456122092
OtherID: 1456117035
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Lynparza,olaparib
DOI: 10.31525/cmr-c89d5c(Journal) (5538756-N )
DOI: 10.31525/cmr-11222fa(Journal)
==========================================================

Created: 2019-10-13 17:35:06.0
ConfID: 5538778
CauseID: 1456122178
OtherID: 1456122171
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Orphan designation: Eflornithine, Treatment of familial adenomatous polyposis
DOI: 10.31525/cmr-1161dcb(Journal) (5538778-N )
DOI: 10.31525/cmr-1161dd5(Journal)
==========================================================

Created: 2019-10-13 20:35:51.0
ConfID: 5538783
CauseID: 1456127194
OtherID: 1456118959, 1456127194
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
DOI: 10.31525/ct1-nct03890445(Journal) (5538783-N )
DOI: 10.31525/ct1-nct04022083(Journal)
==========================================================

Created: 2019-10-13 17:46:36.0
ConfID: 5538840
CauseID: 1456122477
OtherID: 1456118309
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Expert Statements Concerning the Tapering of Oral Corticosteroids (OCS) for the Treatment of Asthma
DOI: 10.31525/ct1-nct03899740(Journal) (5538840-N )
DOI: 10.31525/ct1-nct03934801(Journal)
==========================================================

Created: 2019-10-13 19:09:21.0
ConfID: 5539094
CauseID: 1456124875
OtherID: 1456121775
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma
DOI: 10.31525/fda1-ucm636395.htm(Journal) (5539094-N )
DOI: 10.31525/cmr-14804d4(Journal)
==========================================================

Created: 2019-10-13 19:09:21.0
ConfID: 5539095
CauseID: 1456124875
OtherID: 1456117067
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer
DOI: 10.31525/fda1-ucm633065.htm(Journal) (5539095-N )
DOI: 10.31525/cmr-14804dc(Journal)
==========================================================

Created: 2019-10-13 19:09:21.0
ConfID: 5539096
CauseID: 1456124875
OtherID: 1456117374
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma
DOI: 10.31525/fda1-ucm635910.htm(Journal) (5539096-N )
DOI: 10.31525/cmr-14804d7(Journal)
==========================================================

Created: 2019-10-13 19:09:21.0
ConfID: 5539097
CauseID: 1456124875
OtherID: 1456117357
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)
DOI: 10.31525/fda1-ucm635857.htm(Journal) (5539097-N )
DOI: 10.31525/cmr-14804da(Journal)
==========================================================

Created: 2019-10-13 19:09:21.0
ConfID: 5539098
CauseID: 1456124875
OtherID: 1456116764
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2018,FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
DOI: 10.31525/fda1-ucm629090.htm(Journal) (5539098-N )
DOI: 10.31525/cmr-18ea492(Journal)
==========================================================

Created: 2019-10-13 19:09:36.0
ConfID: 5539100
CauseID: 1456124881
OtherID: 1456116924
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices
DOI: 10.31525/fda2-ucm631412.htm(Journal) (5539100-N )
DOI: 10.31525/cmr-14804ef(Journal)
==========================================================

Created: 2019-10-13 19:12:21.0
ConfID: 5539106
CauseID: 1456124959
OtherID: 1456124067
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
DOI: 10.31525/ct1-nct03963505(Journal) (5539106-N )
DOI: 10.31525/ct1-nct03978494(Journal)
==========================================================

Created: 2019-10-13 19:19:21.0
ConfID: 5539115
CauseID: 1456125205
OtherID: 1456117534
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
DOI: 10.31525/ct1-nct03910270(Journal) (5539115-N )
DOI: 10.31525/ct1-nct03983928(Journal)
==========================================================

Created: 2019-10-13 19:43:06.0
ConfID: 5539147
CauseID: 1456125954
OtherID: 1456125919
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Novel Training Environment to Normalize Altered Finger Force Direction Post Stroke
DOI: 10.31525/ct1-nct03995069(Journal) (5539147-N )
DOI: 10.31525/ct1-nct03993756(Journal)
==========================================================

Created: 2019-10-13 19:43:21.0
ConfID: 5539149
CauseID: 1456125961
OtherID: 1456124533
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
DOI: 10.31525/ct1-nct03972436(Journal) (5539149-N )
DOI: 10.31525/ct1-nct03993678(Journal)
==========================================================

Created: 2019-10-13 20:59:21.0
ConfID: 5539166
CauseID: 1456127743
OtherID: 1456116897, 1456127743
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Tecentriq,atezolizumab
DOI: 10.31525/cmr-a30d19(Journal) (5539166-N )
DOI: 10.31525/cmr-189d3ad(Journal)
==========================================================

Created: 2019-10-13 19:55:51.0
ConfID: 5539168
CauseID: 1456126271
OtherID: 1456116897
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Forxiga,dapagliflozin
DOI: 10.31525/cmr-a30d14(Journal) (5539168-N )
DOI: 10.31525/cmr-1658a65(Journal)
==========================================================

Created: 2019-10-13 23:05:20.0
ConfID: 5539169
CauseID: 1456133829
OtherID: 1456117035, 1456133829
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Dupixent,dupilumab
DOI: 10.31525/cmr-c89d55(Journal) (5539169-N )
DOI: 10.31525/cmr-1d401b1(Journal)
==========================================================

Created: 2019-10-13 20:21:06.0
ConfID: 5539191
CauseID: 1456126870
OtherID: 1456126361
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
DOI: 10.31525/ct1-nct04002947(Journal) (5539191-N )
DOI: 10.31525/ct1-nct04014348(Journal)
==========================================================

Created: 2019-10-13 20:37:51.0
ConfID: 5539199
CauseID: 1456127236
OtherID: 1456124917
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
DOI: 10.31525/ct1-nct03978858(Journal) (5539199-N )
DOI: 10.31525/ct1-nct04023526(Journal)
==========================================================

Created: 2019-10-13 20:59:36.0
ConfID: 5539262
CauseID: 1456127749
OtherID: 1456116890
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Keytruda,pembrolizumab
DOI: 10.31525/cmr-a30d0d(Journal) (5539262-N )
DOI: 10.31525/cmr-189d3b1(Journal)
==========================================================

Created: 2019-10-13 21:12:06.0
ConfID: 5539327
CauseID: 1456130134
OtherID: 1456120263
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Intravenous Iloprost in Subjects With Symptomatic Raynaud''s Phenomenon Secondary to Systemic Sclerosis
DOI: 10.31525/ct1-nct03867097(Journal) (5539327-N )
DOI: 10.31525/ct1-nct04040322(Journal)
==========================================================

Created: 2019-10-13 21:28:36.0
ConfID: 5539468
CauseID: 1456130529
OtherID: 1456125341
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Orphan designation: Diacerein, Treatment of epidermolysis bullosa
DOI: 10.31525/cmr-152a1a1(Journal) (5539468-N )
DOI: 10.31525/cmr-19c815d(Journal)
==========================================================

Created: 2019-10-13 22:47:51.0
ConfID: 5540525
CauseID: 1456133101
OtherID: 1456122564
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,GEN1042 Safety Trial in Subjects With Malignant Solid Tumors
DOI: 10.31525/ct1-nct03937024(Journal) (5540525-N )
DOI: 10.31525/ct1-nct04083599(Journal)
==========================================================

Created: 2019-10-13 23:05:20.0
ConfID: 5540778
CauseID: 1456133829
OtherID: 1456127743
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Summary of opinion: Lucentis,ranibizumab
DOI: 10.31525/cmr-189d3a0(Journal) (5540778-N )
DOI: 10.31525/cmr-1d401ab(Journal)
==========================================================

Created: 2019-10-13 23:13:35.0
ConfID: 5540884
CauseID: 1456134083
OtherID: 1456133969
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Phase I Clinical Trial of One Vaccine
DOI: 10.31525/ct1-nct04099303(Journal) (5540884-N )
DOI: 10.31525/ct1-nct04100772(Journal)
==========================================================

Created: 2019-10-13 23:59:35.0
ConfID: 5541311
CauseID: 1456135839
OtherID: 1456121839
JT: Case Medical Research
MD: Kernel Networks Inc.,null,null,null,2019,Orphan designation:
DOI: 10.31525/cmr-10e7699(Journal) (5541311-N )
DOI: 10.31525/cmr-1efde81(Journal)
==========================================================

Created: 2019-10-29 15:21:01.0
ConfID: 5553188
CauseID: 1457225193
OtherID: 1457224014
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Leukemia, Myeloid,Leukemia, Lymphoid, Date of authorisation: 01/07/2013, Revision: 20, Status: Authorised
DOI: 10.31525/cmr-2071be8(Journal) (5553188-N )
DOI: 10.31525/cmr-207280d(Journal)
==========================================================

Created: 2019-11-06 07:22:49.0
ConfID: 5555916
CauseID: 1457743628
OtherID: 1457700130
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations
DOI: 10.31525/cmr-2106c4c(Journal) (5555916-N )
DOI: 10.31525/cmr-21156ed(Journal)
==========================================================

Created: 2019-11-06 07:22:49.0
ConfID: 5555917
CauseID: 1457743628
OtherID: 1457340905
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Udenyca, pegfilgrastim, Neutropenia, Date of authorisation: 21/09/2018, Revision: 1, Status: Authorised
DOI: 10.31525/cmr-208eb13(Journal) (5555917-N )
DOI: 10.31525/cmr-21156ec(Journal)
==========================================================

Created: 2019-11-06 07:31:46.0
ConfID: 5555918
CauseID: 1457743974
OtherID: 1457340945
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Eucreas, vildagliptin / metformin, Diabetes Mellitus, Type 2, Date of authorisation: 14/11/2007, Revision: 18, Status: Authorised
DOI: 10.31525/cmr-208eb19(Journal) (5555918-N )
DOI: 10.31525/cmr-21156f0(Journal)
==========================================================

Created: 2019-11-06 08:22:46.0
ConfID: 5555944
CauseID: 1457745440
OtherID: 1457341081
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 31, Status: Authorised
DOI: 10.31525/cmr-208eb29(Journal) (5555944-N )
DOI: 10.31525/cmr-2115709(Journal)
==========================================================

Created: 2019-11-06 08:25:46.0
ConfID: 5555945
CauseID: 1457745527
OtherID: 1457341081
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Truberzi, eluxadoline, Irritable Bowel Syndrome,Diarrhea, Date of authorisation: 19/09/2016, Revision: 5, Status: Authorised
DOI: 10.31525/cmr-208eb2c(Journal) (5555945-N )
DOI: 10.31525/cmr-211570b(Journal)
==========================================================

Created: 2019-11-06 08:25:46.0
ConfID: 5555946
CauseID: 1457745527
OtherID: 1457340905
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Atriance, nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 22/08/2007, Revision: 20, Status: Authorised
DOI: 10.31525/cmr-208eb08(Journal) (5555946-N )
DOI: 10.31525/cmr-211570d(Journal)
==========================================================

Created: 2019-11-06 08:31:46.0
ConfID: 5555947
CauseID: 1457745689
OtherID: 1457340945
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Sildenafil Teva, sildenafil, Erectile Dysfunction, Date of authorisation: 30/11/2009, Revision: 14, Status: Authorised
DOI: 10.31525/cmr-208eb14(Journal) (5555947-N )
DOI: 10.31525/cmr-2115715(Journal)
==========================================================

Created: 2019-11-06 08:31:46.0
ConfID: 5555948
CauseID: 1457745689
OtherID: 1457340905
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic,Psoriasis,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid,Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised
DOI: 10.31525/cmr-208eb0e(Journal) (5555948-N )
DOI: 10.31525/cmr-2115716(Journal)
==========================================================

Created: 2019-11-06 08:34:46.0
ConfID: 5555949
CauseID: 1457745726
OtherID: 1457719417
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Axura, memantine, Alzheimer Disease, Date of authorisation: 17/05/2002, Revision: 25, Status: Authorised
DOI: 10.31525/cmr-210d408(Journal) (5555949-N )
DOI: 10.31525/cmr-2115718(Journal)
==========================================================

Created: 2019-11-06 08:34:46.0
ConfID: 5555950
CauseID: 1457745726
OtherID: 1457719417
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Alzheimer Disease, Date of authorisation: 22/11/2012, Revision: 6, Status: Authorised
DOI: 10.31525/cmr-210d406(Journal) (5555950-N )
DOI: 10.31525/cmr-211571a(Journal)
==========================================================

Created: 2019-11-06 08:34:46.0
ConfID: 5555951
CauseID: 1457745726
OtherID: 1457340686
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Temodal, temozolomide, Glioma,Glioblastoma, Date of authorisation: 26/01/1999, Revision: 32, Status: Authorised
DOI: 10.31525/cmr-208eb01(Journal) (5555951-N )
DOI: 10.31525/cmr-211571b(Journal)
==========================================================

Created: 2019-11-07 01:02:53.0
ConfID: 5556111
CauseID: 1457783901
OtherID: 1457749076
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases
DOI: 10.31525/cmr-2118045(Journal) (5556111-N )
DOI: 10.31525/cmr-21180c0(Journal)
==========================================================

Created: 2019-11-08 07:47:25.0
ConfID: 5556230
CauseID: 1457896331
OtherID: 1457896311
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Telmisartan Teva Pharma, telmisartan, Hypertension, Date of authorisation: 03/10/2011, Revision: 8, Status: Authorised
DOI: 10.31525/cmr-213770a(Journal) (5556230-N )
DOI: 10.31525/cmr-213fe29(Journal)
==========================================================

Created: 2019-11-08 07:47:25.0
ConfID: 5556231
CauseID: 1457896331
OtherID: 1457896312
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Gaucher Disease, Date of authorisation: 26/08/2010, Revision: 12, Status: Authorised
DOI: 10.31525/cmr-213770c(Journal) (5556231-N )
DOI: 10.31525/cmr-213fe2e(Journal)
==========================================================

Created: 2019-11-08 07:47:25.0
ConfID: 5556232
CauseID: 1457896331
OtherID: 1457896310
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke,Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 3, Status: Authorised
DOI: 10.31525/cmr-2137704(Journal) (5556232-N )
DOI: 10.31525/cmr-213fe2f(Journal)
==========================================================

Created: 2019-11-08 13:29:27.0
ConfID: 5556239
CauseID: 1457908353
OtherID: 1457905139
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first therapy to treat patients with rare blood disorder
DOI: 10.31525/cmr-2144348(Journal) (5556239-N )
DOI: 10.31525/cmr-2144311(Journal)
==========================================================

Created: 2019-11-08 15:23:28.0
ConfID: 5556257
CauseID: 1457911067
OtherID: 1457909330
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves luspatercept-aamt for anemia in patients with beta thalassemia
DOI: 10.31525/cmr-2145be5(Journal) (5556257-N )
DOI: 10.31525/cmr-2145bad(Journal)
==========================================================

Created: 2019-11-08 22:16:19.0
ConfID: 5556261
CauseID: 1457936355
OtherID: 1457896331
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Gilteritinib, Treatment of acute myeloid leukaemia
DOI: 10.31525/cmr-213fe28(Journal) (5556261-N )
DOI: 10.31525/cmr-214c889(Journal)
==========================================================

Created: 2019-11-08 22:18:38.0
ConfID: 5556262
CauseID: 1457936391
OtherID: 1457896331
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Leukemia, Myeloid, Acute, Date of authorisation: 24/10/2019, Status: Authorised
DOI: 10.31525/cmr-213fe2b(Journal) (5556262-N )
DOI: 10.31525/cmr-214c88b(Journal)
==========================================================

Created: 2019-11-12 08:15:59.0
ConfID: 5556406
CauseID: 1458079041
OtherID: 1458058000
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Temozolomide Teva, temozolomide, Glioma,Glioblastoma, Date of authorisation: 28/01/2010, Revision: 18, Status: Authorised
DOI: 10.31525/cmr-218bd13(Journal) (5556406-N )
DOI: 10.31525/cmr-2194ca0(Journal)
==========================================================

Created: 2019-11-13 08:23:53.0
ConfID: 5556772
CauseID: 1458142643
OtherID: 1458116854
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Zaltrap, aflibercept, Colorectal Neoplasms, Date of authorisation: 01/02/2013, Revision: 8, Status: Authorised
DOI: 10.31525/cmr-21a0e86(Journal) (5556772-N )
DOI: 10.31525/cmr-21aa048(Journal)
==========================================================

Created: 2019-11-14 00:29:08.0
ConfID: 5556859
CauseID: 1458186019
OtherID: 1458142643
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Buccolam, midazolam, Epilepsy, Date of authorisation: 04/09/2011, Revision: 9, Status: Authorised
DOI: 10.31525/cmr-21aa047(Journal) (5556859-N )
DOI: 10.31525/cmr-21b600e(Journal)
==========================================================

Created: 2019-11-14 15:38:18.0
ConfID: 5557579
CauseID: 1458225308
OtherID: 1458225170
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
DOI: 10.31525/cmr-21c561c(Journal) (5557579-N )
DOI: 10.31525/cmr-21c564f(Journal)
==========================================================

Created: 2019-11-14 17:50:21.0
ConfID: 5557595
CauseID: 1458229860
OtherID: 1458229859
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance
DOI: 10.31525/cmr-21c764f(Journal) (5557595-N )
DOI: 10.31525/cmr-21c7618(Journal)
==========================================================

Created: 2019-11-14 22:21:51.0
ConfID: 5557600
CauseID: 1458247895
OtherID: 1458211941
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: drotrecogin alfa (activated), Treatment of acute respiratory distress syndrome (ARDS)
DOI: 10.31525/cmr-21bf3e6(Journal) (5557600-N )
DOI: 10.31525/cmr-21cb18f(Journal)
==========================================================

Created: 2019-11-14 22:23:36.0
ConfID: 5557601
CauseID: 1458247908
OtherID: 1458211941
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: eptacog alfa (activated), Treatment of diffuse alveolar haemorrhage
DOI: 10.31525/cmr-21bf3e8(Journal) (5557601-N )
DOI: 10.31525/cmr-21cb197(Journal)
==========================================================

Created: 2019-11-15 09:16:43.0
ConfID: 5557626
CauseID: 1458269771
OtherID: 1458247895
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisation: 27/06/2006, Revision: 28, Status: Authorised
DOI: 10.31525/cmr-21cb186(Journal) (5557626-N )
DOI: 10.31525/cmr-21d478e(Journal)
==========================================================

Created: 2019-11-15 10:56:31.0
ConfID: 5557636
CauseID: 1458273247
OtherID: 1458272101
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma
DOI: 10.31525/cmr-21d603c(Journal) (5557636-N )
DOI: 10.31525/cmr-21d601b(Journal)
==========================================================

Created: 2019-11-15 15:02:26.0
ConfID: 5557649
CauseID: 1458285725
OtherID: 1458285611
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
DOI: 10.31525/cmr-21da016(Journal) (5557649-N )
DOI: 10.31525/cmr-21da039(Journal)
==========================================================

Created: 2019-11-15 15:32:33.0
ConfID: 5557655
CauseID: 1458286886
OtherID: 1458286883
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves crizanlizumab-tmca for sickle cell disease
DOI: 10.31525/cmr-21da79c(Journal) (5557655-N )
DOI: 10.31525/cmr-21da779(Journal)
==========================================================

Created: 2019-11-15 17:17:34.0
ConfID: 5557659
CauseID: 1458292564
OtherID: 1458292009
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first contact lens indicated to slow the progression of nearsightedness in children
DOI: 10.31525/cmr-21dbdc1(Journal) (5557659-N )
DOI: 10.31525/cmr-21dc015(Journal)
==========================================================

Created: 2019-11-15 18:41:34.0
ConfID: 5557662
CauseID: 1458298259
OtherID: 1458298255
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
DOI: 10.31525/cmr-21dd3e7(Journal) (5557662-N )
DOI: 10.31525/cmr-21dd3c5(Journal)
==========================================================

Created: 2019-11-15 22:19:16.0
ConfID: 5557663
CauseID: 1458316677
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Clopidogrel / Acetylsalicylic acid Mylan,clopidogrel / acetylsalicylic acid
DOI: 10.31525/cmr-21d4783(Journal) (5557663-N )
DOI: 10.31525/cmr-21e0302(Journal)
==========================================================

Created: 2019-11-15 22:22:16.0
ConfID: 5557664
CauseID: 1458316779
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Polivy,polatuzumab vedotin
DOI: 10.31525/cmr-21d4782(Journal) (5557664-N )
DOI: 10.31525/cmr-21e0304(Journal)
==========================================================

Created: 2019-11-15 22:22:16.0
ConfID: 5557665
CauseID: 1458316779
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Kadcyla,trastuzumab emtansine
DOI: 10.31525/cmr-21d4785(Journal) (5557665-N )
DOI: 10.31525/cmr-21e0308(Journal)
==========================================================

Created: 2019-11-15 22:22:16.0
ConfID: 5557666
CauseID: 1458316779
OtherID: 1458268790
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Isturisa,osilodrostat
DOI: 10.31525/cmr-21d477d(Journal) (5557666-N )
DOI: 10.31525/cmr-21e030a(Journal)
==========================================================

Created: 2019-11-15 22:22:16.0
ConfID: 5557667
CauseID: 1458316779
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Deferasirox Accord,deferasirox
DOI: 10.31525/cmr-21d4788(Journal) (5557667-N )
DOI: 10.31525/cmr-21e030d(Journal)
==========================================================

Created: 2019-11-15 22:23:00.0
ConfID: 5557668
CauseID: 1458316797
OtherID: 1458269771
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Sunosi,solriamfetol
DOI: 10.31525/cmr-21d478a(Journal) (5557668-N )
DOI: 10.31525/cmr-21e030f(Journal)
==========================================================

Created: 2019-11-15 22:23:00.0
ConfID: 5557669
CauseID: 1458316797
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Tavlesse,fostamatinib
DOI: 10.31525/cmr-21d477f(Journal) (5557669-N )
DOI: 10.31525/cmr-21e0311(Journal)
==========================================================

Created: 2019-11-15 22:23:00.0
ConfID: 5557670
CauseID: 1458316797
OtherID: 1458269763
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Mayzent,siponimod
DOI: 10.31525/cmr-21d4787(Journal) (5557670-N )
DOI: 10.31525/cmr-21e0313(Journal)
==========================================================

Created: 2019-11-18 22:20:29.0
ConfID: 5557732
CauseID: 1458499432
OtherID: 1458462303
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos), daunorubicin / cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 2, Status: Authorised
DOI: 10.31525/cmr-2214258(Journal) (5557732-N )
DOI: 10.31525/cmr-221f78e(Journal)
==========================================================

Created: 2019-11-19 09:31:25.0
ConfID: 5557788
CauseID: 1458536528
OtherID: 1458499432
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde), irinotecan hydrochloride trihydrate, Pancreatic Neoplasms, Date of authorisation: 14/10/2016, Revision: 4, Status: Authorised
DOI: 10.31525/cmr-221f799(Journal) (5557788-N )
DOI: 10.31525/cmr-22295f9(Journal)
==========================================================

Created: 2019-11-19 09:46:25.0
ConfID: 5557790
CauseID: 1458537585
OtherID: 1458498889
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Carcinoma, Hepatocellular,Carcinoma, Renal Cell, Date of authorisation: 19/07/2006, Revision: 28, Status: Authorised
DOI: 10.31525/cmr-221f788(Journal) (5557790-N )
DOI: 10.31525/cmr-22295ff(Journal)
==========================================================

Created: 2019-11-19 09:46:25.0
ConfID: 5557791
CauseID: 1458537585
OtherID: 1458499328
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Myocet liposomal (previously Myocet), doxorubicin, Breast Neoplasms, Date of authorisation: 13/07/2000, Revision: 21, Status: Authorised
DOI: 10.31525/cmr-221f789(Journal) (5557791-N )
DOI: 10.31525/cmr-2229602(Journal)
==========================================================

Created: 2019-11-19 22:19:17.0
ConfID: 5557835
CauseID: 1458591748
OtherID: 1458537585
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol, Treatment of cystic fibrosis
DOI: 10.31525/cmr-22295fd(Journal) (5557835-N )
DOI: 10.31525/cmr-223490b(Journal)
==========================================================

Created: 2019-11-19 22:22:17.0
ConfID: 5557837
CauseID: 1458591915
OtherID: 1458537585
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Invanz, ertapenem, Community-Acquired Infections,Streptococcal Infections,Staphylococcal Infections,Gram-Negative Bacterial Infections,Surgical Wound Infection,Pneumonia, Bacterial, Date of authorisation: 18/04/2002, Revision: 22, Status: Authorised
DOI: 10.31525/cmr-2229600(Journal) (5557837-N )
DOI: 10.31525/cmr-2234913(Journal)
==========================================================

Created: 2019-11-19 22:22:17.0
ConfID: 5557838
CauseID: 1458591915
OtherID: 1458537687
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotropic factor, Treatment of macular telangiectasia type 2
DOI: 10.31525/cmr-2229607(Journal) (5557838-N )
DOI: 10.31525/cmr-2234915(Journal)
==========================================================

Created: 2019-11-20 09:49:59.0
ConfID: 5557876
CauseID: 1458633301
OtherID: 1458591748
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Autologous collagen type II-specific regulatory T cells, Treatment of non-infectious uveitis
DOI: 10.31525/cmr-223490d(Journal) (5557876-N )
DOI: 10.31525/cmr-223e99f(Journal)
==========================================================

Created: 2019-11-20 13:26:00.0
ConfID: 5557897
CauseID: 1458643804
OtherID: 1458642545
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first treatment for inherited rare disease
DOI: 10.31525/cmr-2241547(Journal) (5557897-N )
DOI: 10.31525/cmr-22415e4(Journal)
==========================================================

Created: 2019-11-20 14:23:01.0
ConfID: 5557898
CauseID: 1458645919
OtherID: 1458645876
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves givosiran for acute hepatic porphyria
DOI: 10.31525/cmr-2242de3(Journal) (5557898-N )
DOI: 10.31525/cmr-2242e81(Journal)
==========================================================

Created: 2019-11-20 22:16:19.0
ConfID: 5557928
CauseID: 1458656993
OtherID: 1458632691
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Eculizumab, Treatment myasthenia gravis
DOI: 10.31525/cmr-223e998(Journal) (5557928-N )
DOI: 10.31525/cmr-2249a87(Journal)
==========================================================

Created: 2019-11-20 22:19:19.0
ConfID: 5557929
CauseID: 1458657107
OtherID: 1458632985
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Halofuginone hydrobromide, Treatment of systemic sclerosis
DOI: 10.31525/cmr-223e999(Journal) (5557929-N )
DOI: 10.31525/cmr-2249a89(Journal)
==========================================================

Created: 2019-11-20 22:20:47.0
ConfID: 5557930
CauseID: 1458657115
OtherID: 1458632413
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Recombinant human tissue non-specific alkaline phosphatase - Fc - deca-aspartate fusion protein, Treatment of hypophosphatasia
DOI: 10.31525/cmr-223e996(Journal) (5557930-N )
DOI: 10.31525/cmr-2249a8b(Journal)
==========================================================

Created: 2019-11-20 22:22:03.0
ConfID: 5557931
CauseID: 1458657122
OtherID: 1458633301
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Eculizumab, Treatment of atypical haemolytic uraemic syndrome (aHUS)
DOI: 10.31525/cmr-223e9a0(Journal) (5557931-N )
DOI: 10.31525/cmr-2249a99(Journal)
==========================================================

Created: 2019-11-20 22:23:23.0
ConfID: 5557932
CauseID: 1458657130
OtherID: 1458633152
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Rixubis, nonacog gamma, Hemophilia B, Date of authorisation: 19/12/2014, Revision: 7, Status: Authorised
DOI: 10.31525/cmr-223e99a(Journal) (5557932-N )
DOI: 10.31525/cmr-2249a9d(Journal)
==========================================================

Created: 2019-11-20 22:23:23.0
ConfID: 5557933
CauseID: 1458657130
OtherID: 1458633152
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Recombinant human lysosomal acid lipase, Treatment of lysosomal acid lipase deficiency
DOI: 10.31525/cmr-223e99b(Journal) (5557933-N )
DOI: 10.31525/cmr-2249a9f(Journal)
==========================================================

Created: 2019-11-21 11:50:42.0
ConfID: 5557959
CauseID: 1458692150
OtherID: 1458689886
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
DOI: 10.31525/cmr-2254e2c(Journal) (5557959-N )
DOI: 10.31525/cmr-2254e72(Journal)
==========================================================

Created: 2019-11-21 15:02:44.0
ConfID: 5557961
CauseID: 1458697492
OtherID: 1458697491
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Project Orbis: FDA approves acalabrutinib for CLL and SLL
DOI: 10.31525/cmr-2258983(Journal) (5557961-N )
DOI: 10.31525/cmr-225893e(Journal)
==========================================================

Created: 2019-11-21 16:56:45.0
ConfID: 5557966
CauseID: 1458700881
OtherID: 1458700880
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new treatment for adults with partial-onset seizures
DOI: 10.31525/cmr-225a494(Journal) (5557966-N )
DOI: 10.31525/cmr-225a44f(Journal)
==========================================================

Created: 2019-11-22 22:04:40.0
ConfID: 5558200
CauseID: 1458766631
OtherID: 1458747353
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Trevicta (previously Paliperidone Janssen), paliperidone, Schizophrenia, Date of authorisation: 05/12/2014, Revision: 9, Status: Authorised
DOI: 10.31525/cmr-22690d7(Journal) (5558200-N )
DOI: 10.31525/cmr-2273da0(Journal)
==========================================================

Created: 2019-11-22 22:04:40.0
ConfID: 5558201
CauseID: 1458766631
OtherID: 1458747353
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Silodyx, silodosin, Prostatic Hyperplasia, Date of authorisation: 29/01/2010, Revision: 13, Status: Authorised
DOI: 10.31525/cmr-22690d6(Journal) (5558201-N )
DOI: 10.31525/cmr-2273da2(Journal)
==========================================================

Created: 2019-11-22 22:10:40.0
ConfID: 5558202
CauseID: 1458766758
OtherID: 1458747353
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Ivozall, clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 14/11/2019, Status: Authorised
DOI: 10.31525/cmr-22690d5(Journal) (5558202-N )
DOI: 10.31525/cmr-2273da3(Journal)
==========================================================

Created: 2019-11-25 15:17:32.0
ConfID: 5558536
CauseID: 1458839181
OtherID: 1458838938
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves novel treatment to target abnormality in sickle cell disease
DOI: 10.31525/cmr-22ad1aa(Journal) (5558536-N )
DOI: 10.31525/cmr-22ad310(Journal)
==========================================================

Created: 2019-11-25 16:11:32.0
ConfID: 5558538
CauseID: 1458842526
OtherID: 1458842000
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves voxelotor for sickle cell disease
DOI: 10.31525/cmr-22addf8(Journal) (5558538-N )
DOI: 10.31525/cmr-22adf5f(Journal)
==========================================================

Created: 2019-11-25 17:56:33.0
ConfID: 5558542
CauseID: 1458848540
OtherID: 1458848278
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves system for the delivery of ear tubes under local anesthesia to treat ear infection
DOI: 10.31525/cmr-22af694(Journal) (5558542-N )
DOI: 10.31525/cmr-22af7fa(Journal)
==========================================================

Created: 2019-11-25 22:19:09.0
ConfID: 5558554
CauseID: 1458859150
OtherID: 1458825747
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Bortezomib Fresenius Kabi, bortezomib, Multiple Myeloma, Date of authorisation: 14/11/2019, Status: Authorised
DOI: 10.31525/cmr-22a8bb6(Journal) (5558554-N )
DOI: 10.31525/cmr-22b320c(Journal)
==========================================================

Created: 2019-11-26 10:36:15.0
ConfID: 5558593
CauseID: 1458898039
OtherID: 1458859150
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Votrient, pazopanib, Carcinoma, Renal Cell, Date of authorisation: 14/06/2010, Revision: 22, Status: Authorised
DOI: 10.31525/cmr-22b3212(Journal) (5558593-N )
DOI: 10.31525/cmr-22bdf50(Journal)
==========================================================

Created: 2019-11-26 10:44:39.0
ConfID: 5558596
CauseID: 1458898308
OtherID: 1458859150
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one, Treatment of follicular lymphoma
DOI: 10.31525/cmr-22b3210(Journal) (5558596-N )
DOI: 10.31525/cmr-22bdf53(Journal)
==========================================================

Created: 2019-11-26 10:46:42.0
ConfID: 5558597
CauseID: 1458898383
OtherID: 1458859175
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (duvelisib), Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma
DOI: 10.31525/cmr-22b3214(Journal) (5558597-N )
DOI: 10.31525/cmr-22bdf56(Journal)
==========================================================

Created: 2019-11-26 10:49:34.0
ConfID: 5558598
CauseID: 1458898458
OtherID: 1457762672
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
DOI: 10.31525/ct1-nct04146363(Journal) (5558598-N )
DOI: 10.31525/ct1-nct04178967(Journal)
==========================================================

Created: 2019-11-26 22:21:46.0
ConfID: 5558616
CauseID: 1458920642
OtherID: 1458898408
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Vectibix, panitumumab, Colorectal Neoplasms, Date of authorisation: 03/12/2007, Revision: 31, Status: Authorised
DOI: 10.31525/cmr-22bdf5d(Journal) (5558616-N )
DOI: 10.31525/cmr-22c8395(Journal)
==========================================================

Created: 2019-11-26 22:22:54.0
ConfID: 5558617
CauseID: 1458920687
OtherID: 1458898383
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Arsenic trioxide Accord, arsenic trioxide, Leukemia, Promyelocytic, Acute, Date of authorisation: 14/11/2019, Status: Authorised
DOI: 10.31525/cmr-22bdf5a(Journal) (5558617-N )
DOI: 10.31525/cmr-22c83a2(Journal)
==========================================================

Created: 2019-11-27 10:41:04.0
ConfID: 5558670
CauseID: 1458950866
OtherID: 1458920687
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Deferiprone Lipomed, deferiprone, Iron Overload,beta-Thalassemia, Date of authorisation: 19/09/2018, Revision: 1, Status: Authorised
DOI: 10.31525/cmr-22c839d(Journal) (5558670-N )
DOI: 10.31525/cmr-22d32ef(Journal)
==========================================================

Created: 2019-11-27 10:49:59.0
ConfID: 5558674
CauseID: 1458951018
OtherID: 1458920642
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Oprymea, pramipexole, Parkinson Disease, Date of authorisation: 12/09/2008, Revision: 19, Status: Authorised
DOI: 10.31525/cmr-22c8398(Journal) (5558674-N )
DOI: 10.31525/cmr-22d32fa(Journal)
==========================================================

Created: 2019-11-29 22:23:11.0
ConfID: 5559040
CauseID: 1459150125
OtherID: 1459074089
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Senstend, lidocaine / prilocaine, Premature Ejaculation, Date of authorisation: 14/11/2019, Status: Authorised
DOI: 10.31525/cmr-22fda2d(Journal) (5559040-N )
DOI: 10.31525/cmr-2307809(Journal)
==========================================================

Created: 2019-12-02 22:28:32.0
ConfID: 5559181
CauseID: 1459248780
OtherID: 1459248317
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: S-acetyl-(S)-4''-phosphopantetheine, calcium salt, Treatment of pantothenate-kinase-associated neurodegeneration
DOI: 10.31525/cmr-2346c83(Journal) (5559181-N )
DOI: 10.31525/cmr-23470be(Journal)
==========================================================

Created: 2019-12-03 22:28:36.0
ConfID: 5559587
CauseID: 1459310109
OtherID: 1459309704
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Glaucoma, Open-Angle,Ocular Hypertension, Date of authorisation: 19/11/2019, Status: Authorised
DOI: 10.31525/cmr-235be0f(Journal) (5559587-N )
DOI: 10.31525/cmr-235c45b(Journal)
==========================================================

Created: 2019-12-03 22:28:36.0
ConfID: 5559588
CauseID: 1459310109
OtherID: 1459309715
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Synagis, palivizumab, Respiratory Syncytial Virus Infections, Date of authorisation: 13/08/1999, Revision: 40, Status: Authorised
DOI: 10.31525/cmr-235be14(Journal) (5559588-N )
DOI: 10.31525/cmr-235c45c(Journal)
==========================================================

Created: 2019-12-03 22:28:36.0
ConfID: 5559589
CauseID: 1459310109
OtherID: 1459309704
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: (R)-troloxamide quinone, Treatment of amyotrophic lateral sclerosis
DOI: 10.31525/cmr-235be11(Journal) (5559589-N )
DOI: 10.31525/cmr-235c45d(Journal)
==========================================================

Created: 2019-12-03 22:28:50.0
ConfID: 5559590
CauseID: 1459310112
OtherID: 1459309704
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Vatiquinone, Treatment of RARS2 syndrome
DOI: 10.31525/cmr-235be0c(Journal) (5559590-N )
DOI: 10.31525/cmr-235c465(Journal)
==========================================================

Created: 2019-12-03 22:28:50.0
ConfID: 5559591
CauseID: 1459310112
OtherID: 1459309715
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Alpha-tocotrienol quinone, Treatment of Leigh syndrome
DOI: 10.31525/cmr-235be17(Journal) (5559591-N )
DOI: 10.31525/cmr-235c467(Journal)
==========================================================

Created: 2019-12-04 22:43:23.0
ConfID: 5559711
CauseID: 1459361952
OtherID: 1459361039
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl, Treatment of familial cerebral cavernous malformations
DOI: 10.31525/cmr-2370f81(Journal) (5559711-N )
DOI: 10.31525/cmr-23717fa(Journal)
==========================================================

Created: 2019-12-04 22:55:23.0
ConfID: 5559712
CauseID: 1459362141
OtherID: 1459361561
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Teysuno, tegafur / gimeracil / oteracil, Stomach Neoplasms, Date of authorisation: 14/03/2011, Revision: 16, Status: Authorised
DOI: 10.31525/cmr-2370f89(Journal) (5559712-N )
DOI: 10.31525/cmr-23717fb(Journal)
==========================================================

Created: 2019-12-04 23:03:38.0
ConfID: 5559715
CauseID: 1459362312
OtherID: 1459361561
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: Ivosidenib, Treatment of acute myeloid leukaemia
DOI: 10.31525/cmr-2370f8b(Journal) (5559715-N )
DOI: 10.31525/cmr-23717fe(Journal)
==========================================================

Created: 2019-12-05 12:01:47.0
ConfID: 5559958
CauseID: 1459397159
OtherID: 1459397158
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria
DOI: 10.31525/cmr-237d305(Journal) (5559958-N )
DOI: 10.31525/cmr-237d462(Journal)
==========================================================

Created: 2019-12-05 14:07:48.0
ConfID: 5559959
CauseID: 1459401563
OtherID: 1459401532
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations
DOI: 10.31525/cmr-237f08f(Journal) (5559959-N )
DOI: 10.31525/cmr-237f1eb(Journal)
==========================================================

Created: 2019-12-05 15:28:05.0
ConfID: 5559960
CauseID: 1459402529
OtherID: 1459402458
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first generics of Gilenya
DOI: 10.31525/cmr-2380324(Journal) (5559960-N )
DOI: 10.31525/cmr-238043d(Journal)
==========================================================

Created: 2019-12-09 23:26:42.0
ConfID: 5566620
CauseID: 1459625761
OtherID: 1459620974
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 7, Status: Authorised
DOI: 10.31525/cmr-23da701(Journal) (5566620-N )
DOI: 10.31525/cmr-23dba17(Journal)
==========================================================

Created: 2019-12-10 23:47:48.0
ConfID: 5566715
CauseID: 1459698211
OtherID: 1459693785
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Qtrilmet, metformin hydrochloride / saxagliptin / dapagliflozin, Diabetes Mellitus, Type 2, Date of authorisation: 11/11/2019, Status: Authorised
DOI: 10.31525/cmr-23ef88d(Journal) (5566715-N )
DOI: 10.31525/cmr-23f0dba(Journal)
==========================================================

Created: 2019-12-12 11:56:51.0
ConfID: 5566903
CauseID: 1459849100
OtherID: 1459848898
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA authorizes first test to aid in newborn screening for Duchenne Muscular Dystrophy
DOI: 10.31525/cmr-2410c70(Journal) (5566903-N )
DOI: 10.31525/cmr-2410d98(Journal)
==========================================================

Created: 2019-12-12 18:05:54.0
ConfID: 5566915
CauseID: 1459866757
OtherID: 1459866619
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
DOI: 10.31525/cmr-2416295(Journal) (5566915-N )
DOI: 10.31525/cmr-24163ba(Journal)
==========================================================

Created: 2019-12-12 23:56:56.0
ConfID: 5566922
CauseID: 1459876121
OtherID: 1459873651
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Ervebo, Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live), Hemorrhagic Fever, Ebola, Date of authorisation: 11/11/2019, Status: Authorised
DOI: 10.31525/cmr-2419b89(Journal) (5566922-N )
DOI: 10.31525/cmr-241b4f1(Journal)
==========================================================

Created: 2019-12-13 11:56:59.0
ConfID: 5566984
CauseID: 1459907409
OtherID: 1459907114
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system
DOI: 10.31525/cmr-2425df1(Journal) (5566984-N )
DOI: 10.31525/cmr-2425ec2(Journal)
==========================================================

Created: 2019-12-13 16:36:12.0
ConfID: 5566987
CauseID: 1459913609
OtherID: 1459913368
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups
DOI: 10.31525/cmr-2429ebe(Journal) (5566987-N )
DOI: 10.31525/cmr-242a064(Journal)
==========================================================

Created: 2019-12-14 00:23:53.0
ConfID: 5566997
CauseID: 1459927249
OtherID: 1456430431, 1459927249
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Darzalex,daratumumab
DOI: 10.31525/cmr-1f91907(Journal) (5566997-N )
DOI: 10.31525/cmr-243089c(Journal)
==========================================================

Created: 2019-12-14 00:00:04.0
ConfID: 5567011
CauseID: 1459926806
OtherID: 1459924831
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Vyndaqel,tafamidis
DOI: 10.31525/cmr-242ed15(Journal) (5567011-N )
DOI: 10.31525/cmr-243088f(Journal)
==========================================================

Created: 2019-12-14 00:09:04.0
ConfID: 5567012
CauseID: 1459926939
OtherID: 1459924742
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Sirturo,bedaquiline
DOI: 10.31525/cmr-242ed05(Journal) (5567012-N )
DOI: 10.31525/cmr-2430890(Journal)
==========================================================

Created: 2019-12-14 00:21:01.0
ConfID: 5567013
CauseID: 1459927239
OtherID: 1459924805
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Amsparity,adalimumab
DOI: 10.31525/cmr-242ed11(Journal) (5567013-N )
DOI: 10.31525/cmr-2430891(Journal)
==========================================================

Created: 2019-12-14 00:21:01.0
ConfID: 5567014
CauseID: 1459927239
OtherID: 1459924742
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Erleada,apalutamide
DOI: 10.31525/cmr-242ed06(Journal) (5567014-N )
DOI: 10.31525/cmr-2430892(Journal)
==========================================================

Created: 2019-12-14 00:21:01.0
ConfID: 5567015
CauseID: 1459927239
OtherID: 1459924850
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Cyramza,ramucirumab
DOI: 10.31525/cmr-242ed18(Journal) (5567015-N )
DOI: 10.31525/cmr-2430893(Journal)
==========================================================

Created: 2019-12-14 00:21:01.0
ConfID: 5567016
CauseID: 1459927239
OtherID: 1459924805
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Recarbrio,imipenem / cilastatin / relebactam
DOI: 10.31525/cmr-242ed0d(Journal) (5567016-N )
DOI: 10.31525/cmr-2430894(Journal)
==========================================================

Created: 2019-12-14 00:21:01.0
ConfID: 5567017
CauseID: 1459927239
OtherID: 1459924805
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Dexmedetomidine Accord,dexmedetomidine
DOI: 10.31525/cmr-242ed0a(Journal) (5567017-N )
DOI: 10.31525/cmr-2430895(Journal)
==========================================================

Created: 2019-12-14 00:22:19.0
ConfID: 5567018
CauseID: 1459927246
OtherID: 1459924376
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Akynzeo,netupitant / palonosetron
DOI: 10.31525/cmr-242ed03(Journal) (5567018-N )
DOI: 10.31525/cmr-2430897(Journal)
==========================================================

Created: 2019-12-14 00:22:19.0
ConfID: 5567019
CauseID: 1459927246
OtherID: 1459924805
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Azacitidine Accord,azacitidine
DOI: 10.31525/cmr-242ed0f(Journal) (5567019-N )
DOI: 10.31525/cmr-2430898(Journal)
==========================================================

Created: 2019-12-14 00:22:19.0
ConfID: 5567020
CauseID: 1459927246
OtherID: 1459924015
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Dificlir,fidaxomicin
DOI: 10.31525/cmr-242ed02(Journal) (5567020-N )
DOI: 10.31525/cmr-2430899(Journal)
==========================================================

Created: 2019-12-14 00:22:19.0
ConfID: 5567021
CauseID: 1459927246
OtherID: 1459924742
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Summary of opinion: Beovu,brolucizumab
DOI: 10.31525/cmr-242ed08(Journal) (5567021-N )
DOI: 10.31525/cmr-243089a(Journal)
==========================================================

Created: 2019-12-17 00:31:26.0
ConfID: 5567588
CauseID: 1460043170
OtherID: 1460040889
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Fampyra, fampridine, Multiple Sclerosis, Date of authorisation: 20/07/2011, Revision: 13, Status: Authorised
DOI: 10.31525/cmr-246e186(Journal) (5567588-N )
DOI: 10.31525/cmr-247036b(Journal)
==========================================================

Created: 2019-12-17 08:19:16.0
ConfID: 5567685
CauseID: 1460075371
OtherID: 1460075125
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves enzalutamide for metastatic castration-sensitive prostate cancer
DOI: 10.31525/cmr-2477043(Journal) (5567685-N )
DOI: 10.31525/cmr-247722a(Journal)
==========================================================

Created: 2019-12-17 10:37:17.0
ConfID: 5567693
CauseID: 1460082271
OtherID: 1460081953
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA permits sale of two new reduced nicotine cigarettes through premarket tobacco product application pathway
DOI: 10.31525/cmr-2479042(Journal) (5567693-N )
DOI: 10.31525/cmr-2479228(Journal)
==========================================================

Created: 2019-12-18 17:37:57.0
ConfID: 5567795
CauseID: 1460146184
OtherID: 1460146149
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new type of therapy to treat advanced urothelial cancer
DOI: 10.31525/cmr-24945c5(Journal) (5567795-N )
DOI: 10.31525/cmr-24946a5(Journal)
==========================================================

Created: 2019-12-19 00:51:31.0
ConfID: 5567804
CauseID: 1460162542
OtherID: 1460158364
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Bretaris Genuair, aclidinium bromide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 20/07/2012, Revision: 16, Status: Authorised
DOI: 10.31525/cmr-2498481(Journal) (5567804-N )
DOI: 10.31525/cmr-249aaaa(Journal)
==========================================================

Created: 2019-12-19 00:51:31.0
ConfID: 5567805
CauseID: 1460162542
OtherID: 1460158388
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Orphan designation: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt (niraparib), Treatment of ovarian cancer
DOI: 10.31525/cmr-2498486(Journal) (5567805-N )
DOI: 10.31525/cmr-249aaab(Journal)
==========================================================

Created: 2019-12-19 00:59:48.0
ConfID: 5567806
CauseID: 1460162900
OtherID: 1460158388
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Eklira Genuair, aclidinium bromide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 20/07/2012, Revision: 16, Status: Authorised
DOI: 10.31525/cmr-2498482(Journal) (5567806-N )
DOI: 10.31525/cmr-249aaae(Journal)
==========================================================

Created: 2019-12-19 10:54:04.0
ConfID: 5567830
CauseID: 1460195032
OtherID: 1460194803
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer
DOI: 10.31525/cmr-24a3827(Journal) (5567830-N )
DOI: 10.31525/cmr-24a3968(Journal)
==========================================================

Created: 2019-12-19 19:25:23.0
ConfID: 5567933
CauseID: 1460215883
OtherID: 1460215718
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response
DOI: 10.31525/cmr-24aaf8a(Journal) (5567933-N )
DOI: 10.31525/cmr-24ab0c1(Journal)
==========================================================

Created: 2019-12-20 00:54:10.0
ConfID: 5567939
CauseID: 1460224232
OtherID: 1460220854
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Emend, aprepitant, Vomiting,Postoperative Nausea and Vomiting,Cancer, Date of authorisation: 11/11/2003, Revision: 25, Status: Authorised
DOI: 10.31525/cmr-24ad82a(Journal) (5567939-N )
DOI: 10.31525/cmr-24afe47(Journal)
==========================================================

Created: 2019-12-20 01:15:10.0
ConfID: 5567940
CauseID: 1460224599
OtherID: 1460220854
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Comtan, entacapone, Parkinson Disease, Date of authorisation: 22/09/1998, Revision: 24, Status: Authorised
DOI: 10.31525/cmr-24ad82c(Journal) (5567940-N )
DOI: 10.31525/cmr-24afe4c(Journal)
==========================================================

Created: 2019-12-20 01:15:10.0
ConfID: 5567941
CauseID: 1460224599
OtherID: 1460220839
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Spravato, esketamine, Depressive Disorder, Date of authorisation: 18/12/2019, Status: Authorised
DOI: 10.31525/cmr-24ad822(Journal) (5567941-N )
DOI: 10.31525/cmr-24afe50(Journal)
==========================================================

Created: 2019-12-20 13:56:07.0
ConfID: 5568023
CauseID: 1460263177
OtherID: 1460262928
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
DOI: 10.31525/cmr-24bb467(Journal) (5568023-N )
DOI: 10.31525/cmr-24bb59f(Journal)
==========================================================

Created: 2019-12-20 16:09:39.0
ConfID: 5568056
CauseID: 1460265706
OtherID: 1460265604
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
DOI: 10.31525/cmr-24bd324(Journal) (5568056-N )
DOI: 10.31525/cmr-24bd465(Journal)
==========================================================

Created: 2019-12-21 01:09:42.0
ConfID: 5568073
CauseID: 1460278841
OtherID: 1460274421
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Skin Diseases, Bacterial, Date of authorisation: 16/12/2019, Status: Authorised
DOI: 10.31525/cmr-24c2bc7(Journal) (5568073-N )
DOI: 10.31525/cmr-24c51e6(Journal)
==========================================================

Created: 2019-12-21 01:11:42.0
ConfID: 5568074
CauseID: 1460278872
OtherID: 1460274435
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Kolbam , cholic acid, Metabolism, Inborn Errors, Date of authorisation: 20/11/2015, Revision: 13, Status: Authorised
DOI: 10.31525/cmr-24c2bce(Journal) (5568074-N )
DOI: 10.31525/cmr-24c51ea(Journal)
==========================================================

Created: 2019-12-21 01:13:13.0
ConfID: 5568075
CauseID: 1460278897
OtherID: 1460274421
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Human medicines European public assessment report (EPAR): Pegfilgrastim Mundipharma, pegfilgrastim, Neutropenia, Date of authorisation: 19/12/2019, Status: Authorised
DOI: 10.31525/cmr-24c2bcd(Journal) (5568075-N )
DOI: 10.31525/cmr-24c51f1(Journal)
==========================================================

Created: 2019-12-23 14:39:28.0
ConfID: 5568182
CauseID: 1460352631
OtherID: 1460352459
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new treatment for adults with migraine
DOI: 10.31525/cmr-24fb2ef(Journal) (5568182-N )
DOI: 10.31525/cmr-24fb42d(Journal)
==========================================================

Created: 2019-12-23 15:06:10.0
ConfID: 5568183
CauseID: 1460353353
OtherID: 1460353179
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves first generics of Eliquis
DOI: 10.31525/cmr-24fb91b(Journal) (5568183-N )
DOI: 10.31525/cmr-24fba51(Journal)
==========================================================

Created: 2019-12-30 15:54:19.0
ConfID: 5568501
CauseID: 1460588031
OtherID: 1460588019
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
DOI: 10.31525/cmr-258fffc(Journal) (5568501-N )
DOI: 10.31525/cmr-2590075(Journal)
==========================================================

Created: 2020-01-02 22:43:48.0
ConfID: 5569274
CauseID: 1460750521
OtherID: 1460750508
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
DOI: 10.31525/ct1-nct04214652(Journal) (5569274-N )
DOI: 10.31525/ct1-nct04214639(Journal)
==========================================================

Created: 2020-01-06 22:57:10.0
ConfID: 5569612
CauseID: 1460968966
OtherID: 1460968894
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Orphan designation: Three human monoclonal antibodies against the EBOV glycoprotein, Treatment of Ebola virus disease
DOI: 10.31525/cmr-2629dbe(Journal) (5569612-N )
DOI: 10.31525/cmr-2629dbf(Journal)
==========================================================

Created: 2020-01-06 22:56:37.0
ConfID: 5569613
CauseID: 1460968933
OtherID: 1460968908
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Orphan designation: human monoclonal antibody against activin A, Treatment of fibrodysplasia ossificans progressiva
DOI: 10.31525/cmr-2629db8(Journal) (5569613-N )
DOI: 10.31525/cmr-2629dc2(Journal)
==========================================================

Created: 2020-01-06 22:56:11.0
ConfID: 5569614
CauseID: 1460968908
OtherID: 1460968933
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Orphan designation: Tipifarnib, Treatment of acute myeloid leukaemia
DOI: 10.31525/cmr-2629dc1(Journal) (5569614-N )
DOI: 10.31525/cmr-2629dbc(Journal)
==========================================================

Created: 2020-01-06 22:56:37.0
ConfID: 5569615
CauseID: 1460968933
OtherID: 1460968908
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Leukemia, Myeloid, Acute, Date of refusal: 19/12/2019, Status: Refused
DOI: 10.31525/cmr-2629dbb(Journal) (5569615-N )
DOI: 10.31525/cmr-2629dc4(Journal)
==========================================================

Created: 2020-01-07 23:08:06.0
ConfID: 5569745
CauseID: 1461048161
OtherID: 1461048072
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): TachoSil, human fibrinogen / human thrombin, Hemostasis, Surgical, Date of authorisation: 08/06/2004, Revision: 23, Status: Authorised
DOI: 10.31525/cmr-263f161(Journal) (5569745-N )
DOI: 10.31525/cmr-263f154(Journal)
==========================================================

Created: 2020-01-08 14:20:36.0
ConfID: 5569786
CauseID: 1461120792
OtherID: 1461120022
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
DOI: 10.31525/cmr-264c772(Journal) (5569786-N )
DOI: 10.31525/cmr-264c778(Journal)
==========================================================

Created: 2020-01-09 15:41:47.0
ConfID: 5569898
CauseID: 1461220890
OtherID: 1461220889
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
DOI: 10.31525/cmr-2662c50(Journal) (5569898-N )
DOI: 10.31525/cmr-2662c49(Journal)
==========================================================

Created: 2020-01-09 17:05:47.0
ConfID: 5569904
CauseID: 1461225413
OtherID: 1461225412
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
DOI: 10.31525/cmr-2664001(Journal) (5569904-N )
DOI: 10.31525/cmr-2663ff9(Journal)
==========================================================

Created: 2020-01-09 23:23:50.0
ConfID: 5569914
CauseID: 1461243563
OtherID: 1461243559
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): Nityr, nitisinone, Tyrosinemias, Date of authorisation: 26/07/2018, Revision: 1, Status: Authorised
DOI: 10.31525/cmr-2669898(Journal) (5569914-N )
DOI: 10.31525/cmr-2669890(Journal)
==========================================================

Created: 2020-01-09 23:26:19.0
ConfID: 5569915
CauseID: 1461243673
OtherID: 1461243559
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 28/09/2012, Revision: 9, Status: Authorised
DOI: 10.31525/cmr-266989a(Journal) (5569915-N )
DOI: 10.31525/cmr-2669896(Journal)
==========================================================

Created: 2020-01-10 23:50:03.0
ConfID: 5570376
CauseID: 1461338135
OtherID: 1461337776
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): Xofigo, radium Ra223 dichloride, Prostatic Neoplasms, Date of authorisation: 13/11/2013, Revision: 10, Status: Authorised
DOI: 10.31525/cmr-267ec37(Journal) (5570376-N )
DOI: 10.31525/cmr-267ec31(Journal)
==========================================================

Created: 2020-01-10 23:59:03.0
ConfID: 5570377
CauseID: 1461338397
OtherID: 1461338299
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Human medicines European public assessment report (EPAR): Firmagon, degarelix, Prostatic Neoplasms, Date of authorisation: 17/02/2009, Revision: 14, Status: Authorised
DOI: 10.31525/cmr-267ec3d(Journal) (5570377-N )
DOI: 10.31525/cmr-267ec3a(Journal)
==========================================================

Created: 2020-02-17 22:15:30.0
ConfID: 5577480
CauseID: 1463558256
OtherID: 1463558240
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2020,Pattern Recognition Prosthetic Control
DOI: 10.31525/ct1-nct04272489(Journal) (5577480-N )
DOI: 10.31525/ct1-nct04272593(Journal)
==========================================================

Created: 2020-02-20 22:44:00.0
ConfID: 5577894
CauseID: 1463751353
OtherID: 1445305814
JT: Case Medical Research
MD: Case Medical Research,null,null,null,2019,FDA approves new oral treatment for multiple sclerosis
DOI: 10.31525/fda2-ucm634837.htm(Journal) (5577894-N )
DOI: 10.31525/cmr-29deadf(Journal)